Zefei Jiang
YOU?
Author Swipe
View article: Zanidatamab in combination with docetaxel in first-line HER2-positive breast cancer: results from an open-label, multicenter, phase Ib/II study
Zanidatamab in combination with docetaxel in first-line HER2-positive breast cancer: results from an open-label, multicenter, phase Ib/II study Open
Zanidatamab demonstrated efficacy and a manageable and tolerable safety profile with docetaxel as first-line treatment in patients with HER2-positive breast cancer. These data support the further development of zanidatamab in this patient …
View article: Anal fistula with concomitant perianal cyst: A case report and literature review
Anal fistula with concomitant perianal cyst: A case report and literature review Open
Rationale: Recurrent anal fistula remains a clinical challenge, especially when standard treatment fails to prevent relapse. Adjacent cystic infections may represent an underrecognized contributor to persistent or recurrent disease. Patien…
View article: Chinese expert consensus on clinical diagnosis and treatment of breast cancer targeting HER2
Chinese expert consensus on clinical diagnosis and treatment of breast cancer targeting HER2 Open
The overarching goal of this consensus is to deliver individualized treatment strategies that not only prolong survival but also enhance quality of life, ensuring HER2-positive breast cancer patients receive the most advanced, patient-cent…
View article: Development of a prognostic risk stratification model for HER2-positive breast cancer brain metastasis and its implications in guiding treatment decisions
Development of a prognostic risk stratification model for HER2-positive breast cancer brain metastasis and its implications in guiding treatment decisions Open
Brain metastasis occurs in approximately 50% of patients with advanced HER2-positive breast cancer. Despite improved prognosis, survival remains limited. This study aims to investigate the clinicopathological characteristics of HER2-positi…
View article: Supplementary Methods S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Methods S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Methods 1
View article: Supplementary Figure S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Figure S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Figure 1. Diagram showing patient disposition.
View article: Supplementary Table S6 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S6 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 6: Comparisons of the probabilities of patients that are CTC positive at baseline being a CTC responder (i.e., switching from CTC positive at baseline to CTC negative at first follow-up) between HER2-positive/hormone re…
View article: Data from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Data from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Purpose:The aim of PREDICT was to confirm clinical validity and the potential for clinical utility of serial circulating tumor cell (CTC) enumeration in patients with metastatic breast cancer, focusing on its prognostic value in different …
View article: Supplementary Table S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 1. Clinical trials, multicenter studies, and institutions/centers that provided data sets from MBC patients for the pooled analysis.
View article: Supplementary Figure S3 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Figure S3 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Figure 3: Kaplan-Meier plots of overall survival (OS) according to CTC status at baseline for HER2-positive/hormone receptor-positive tumors(A, B) and HER2-positive/hormone receptor-negative tumors(C, D). Survival time is giv…
View article: Supplementary Table S7 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S7 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 7. Median overall survival (OS) and hazard ratios for the CTC change groups as categorized based on the ≥5 CTC cutoff for CTC positivity (reference group neg/neg) for patients with hormone receptor-positive/HER2-negativ…
View article: Supplementary Table S2 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S2 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 2. Absolute and relative frequencies of CTC change groups and percentage of CTC responders (as categorized according to the ≥1 CTC or ≥5 CTC cutoff for CTC positivity) overall, according to tumor subtypes and according …
View article: Supplementary Table S8 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S8 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 8. Median overall survival (OS) and hazard ratios for the CTC change groups as categorized based on the ≥5 CTC cutoff for CTC positivity (reference group neg/neg) for patients with HER2-positive/ hormone receptor-positi…
View article: Supplementary Figure S4 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Figure S4 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Figure 4. Kaplan-Meier plot of overall survival according to change in CTC status from baseline to first follow-up (cutoff for CTC positivity ≥1 CTC). (A) HER2-positive/hormone receptor-positive tumors; (B) HER2-positive/horm…
View article: Supplementary Table S5 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S5 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 5: Comparisons of the probabilities of patients that are CTC positive at baseline being a CTC responder (i.e., switching from CTC positive at baseline to CTC negative at first follow-up) among tumor subtypes (hormone re…
View article: Supplementary Figure S2 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Figure S2 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Figure 2: Kaplan-Meier plots of overall survival (OS) according to CTC status at baseline for a cutoff for CTC positivity ≥1 CTC (A, B, C) and a cutoff for CTC positivity ≥5 CTCs (D, E, F). Survival time is given as time sinc…
View article: Supplementary Table S9 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S9 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 9. Median overall survival (OS) and hazard ratios for the CTC change groups as categorized based on the ≥5 CTC cutoff for CTC positivity (reference group neg/neg) for patients that received chemotherapy-based or endocri…
View article: Supplementary Table S3 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S3 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 3: Comparisons of the probabilities of being CTC positive among tumor subtypes (hormone receptor-positive/HER2-negative, HER2-positive, triple-negative) according to time point of CTC assessment (baseline, first follow-…
View article: Supplementary Table S4 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Supplementary Table S4 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Supplementary Table 4: Comparisons of the probabilities of being CTC positive betweenHER2- positive/hormone receptor-positive and HER2-positive/hormone receptor-negative tumors according to time point of CTC assessment (baseline, first fol…
View article: OP0102 Efficacy and Safety of Xeligekimab in Radiographic Axial Spondyloarthritis: Results from a Phase 3 Trial
OP0102 Efficacy and Safety of Xeligekimab in Radiographic Axial Spondyloarthritis: Results from a Phase 3 Trial Open
View article: Association between accelerometer-measured physical activity and mortality in cancer survivors: A prospective cohort study from UK Biobank
Association between accelerometer-measured physical activity and mortality in cancer survivors: A prospective cohort study from UK Biobank Open
Active physical activity substantially reduced all-cause mortality in pan-cancer survivors and cancer-specific mortality in cancer survivors of specific sites. However, the benefits were significant only when intensity of physical activity…
View article: Natural surgical risks and age distribution in Chinese patients with Peutz-Jeghers syndrome: Real-world research based on a web survey
Natural surgical risks and age distribution in Chinese patients with Peutz-Jeghers syndrome: Real-world research based on a web survey Open
BACKGROUND Complications arising from the polyps in Peutz-Jeghers syndrome (PJS) have historically been addressed through surgical treatment. Enteroscopic polypectomy is hypothesized to reduce the risk of surgery in PJS. However, the optim…
View article: Efficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy
Efficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy Open
Tyrosine kinase inhibitors (TKIs) and trastuzumab deruxtecan (T-DXd) have shown efficacy in HER2-positive patients with brain metastases (BMs). This paper analyzed the efficacy and safety of T-DXd in HER2-positive breast cancer patients wi…
View article: Global, regional, and national burden of cardiovascular diseases attributable to metabolic risks across all age groups from 1990 to 2021: an analysis of the 2021 global burden of disease study data
Global, regional, and national burden of cardiovascular diseases attributable to metabolic risks across all age groups from 1990 to 2021: an analysis of the 2021 global burden of disease study data Open
View article: Interpretive machine learning predicts short-term mortality risk in elderly sepsis patients
Interpretive machine learning predicts short-term mortality risk in elderly sepsis patients Open
Backgrounds Sepsis is a leading cause of in-hospital mortality. However, its prevalence is increasing among the elderly population. Therefore, early identification and prediction of the risk of death in elderly patients with sepsis is cruc…
View article: Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis Open
Purpose: The aim of PREDICT was to confirm clinical validity and the potential for clinical utility of serial circulating tumor cell (CTC) enumeration in patients with metastatic breast cancer, focusing on its prognostic value in different…
View article: Establishment and validation of post-PCI nomogram in elderly patients with acute coronary syndromes
Establishment and validation of post-PCI nomogram in elderly patients with acute coronary syndromes Open
Objective The objective of this study was to create and validate a clinical prediction model for the incidence of major adverse cardiovascular events (MACE) within one year after percutaneous coronary intervention (PCI) in elderly patients…
View article: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 Open
View article: WKB ameliorates DSS-induced colitis through inhibiting enteric glial cells activation and altering the intestinal microbiota
WKB ameliorates DSS-induced colitis through inhibiting enteric glial cells activation and altering the intestinal microbiota Open
View article: N6-Methyladenosine Promotes the Transcription of c-Src Kinase via IRF1 to Facilitate the Proliferation of Liver Cancer
N6-Methyladenosine Promotes the Transcription of c-Src Kinase via IRF1 to Facilitate the Proliferation of Liver Cancer Open
Results suggested that the METTL3/IRF1/c-Src axis played potential oncogenic roles in liver cancer development and the axis may be a promising therapeutic target in the disease.